All In Biotech

Drug Trial Radar · NCT03205163

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A

Last checked: Nov 19, 2026Latest source record: Apr 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Aug 28, 2017

Primary completion

Nov 12, 2018

Study completion Nov 12, 2018

Sponsor

Lead sponsor
Bioverativ, a Sanofi companySanofi (SNY)
Sponsor type
Industry
First posted
Jul 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose was to assess the safety and tolerability of a single intravenous (IV) administration of BIVV001 in adult previously treated patients (PTPs) with severe hemophilia A.

Conditions

  • Hemophilia A

Interventions

  • Advate (Low Dose)Biological

    Participants received a single IV low dose of Advate 25 IU/kg.

  • Advate (High Dose)Biological

    Participants received a single IV high dose of Advate 65 IU/kg.

  • BIVV001 (Low Dose)Biological

    Participants received single IV low dose of BIVV001 25 IU/kg.

  • BIVV001 (High Dose)Biological

    Participants received single IV high dose of BIVV001 65 IU/kg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During Advate Treatment PeriodTime frame: Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg
  2. Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During BIVV001 Treatment PeriodTime frame: Up to 28 days after BIVV001 administration
  3. Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During Advate Treatment PeriodTime frame: Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg
  4. Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During BIVV001 Treatment PeriodTime frame: Up to 28 days after BIVV001 administration
  5. Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda AssayTime frame: Up to 28 days after BIVV001 administration

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles Medical Center

    Los Angeles, California

  • Indiana Hemophilia and Thrombosis Center

    Indianapolis, Indiana

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • Michigan State University

    East Lansing, Michigan

  • Mississippi Center for Advanced Medicine

    Madison, Mississippi

  • Hemophilia Center of Western PA

    Pittsburgh, Pennsylvania

  • University of Washington

    Seattle, Washington

  • Nara Medical University Hospital

    Kashihara-shi, Nara, Japan

  • Tokyo Medical University Hospital

    Shinjuku-Ku, Tokyo-To, Japan

  • Ogikubo Hospital

    Tokyo, Tokyo-To, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.